Is it time to buy Wood Group shares?

Wood Group is a major casualty of the slowdown in oil and gas upstream activity over the past five years. The company has racked up nearly $700m in net debt and is set for a year of negative free cash flow.

The green energy transition has ravaged Wood Group’s fossil fuel energy business. The decline in upstream spending has directly contributed to Wood Group’s demise. Investors, however, will be rightly critical of the company’s management of the situation.

Although the writing has been on the wall for more than a decade, Wood Group has only recently started to report substantive sustainable energy-related revenues.

Wood Group is doing really interesting things in hydrogen, carbon capture, LNG and waste-to-energy. Sustainable activities made up around 21% of revenue in the recent half-year period, and the company said its sales pipeline is around 40% sustainable solutions related. Some would argue that this is too little, too late. 

Notwithstanding Wood Group’s weighting to fossil fuels and sustainable solutions, the immediate concern is the company’s poor financial position, which was highlighted by a trading update in February. Wood Group shares halved the day it was released.

Be under no illusion that the trading statement released in mid-February deserved the market reaction it got. 

Wood Group is haemorrhaging cash and is being forced to sell off assets to plug an expected negative free cash flow of between $150m – $200m. 

Negative free cash flow is a concern because it raises questions about Wood Group’s ability to manage and improve its debt situation. This is a major red flag and is the main contributor to the 80% decline in the Wood Group share price over the past year.

The company is in trouble. Macro influences have been unkind, and Wood Group could have handled the headwinds better. Adjusted EBITDA more than halved from $885m in 2019 to $423m in 2023.

However, those looking at shares at 26p and attempting to gauge whether now is a good time to buy must consider the future and whether the company has a clear path to recovery.

Shares are trading below 30p for a reason. Wood is struggling to generate cash, and debts are mounting. Cash generation is key to a rebound in shares. The company is disposing of assets to raise cash this year, but selling off assets isn’t a long-term solution. 

Wood is undergoing a cost savings programme that is expected to reduce the cost base by around $145m between 2023 and 2026. Reducing costs will help improve cash generation, but the company desperately needs top-line growth.

Thankfully, the industry may just be turning in Wood’s favour.

The upstream fossil fuel industry is showing signs of increased investment, which will provide much-needed business for Wood Group.

After peaking at $814bn in 2014, annual investment in upstream oil and gas hit lows of around $400bn before steadily picking up to an estimated $580bn in 2024. Forecasters at the International Energy Forum see this increasing to around $780bn by 2030. A continued and steady increase in upstream investment would underpin Wood Group’s growth over the next five years. 

Donald Trump’s approach to oil and gas will be welcomed by Wood Group executives.

Meanwhile, Wood Group continues to win new business from the world’s largest energy companies, including BP, Shell, and Saudi Aramco, and will likely beneift if these major players increase their activity. As an example, Wood recently announced a $120m contract extension with Shell to develop brownfield offshore and onshore assets across the UK.

There could well be a rewarding medium-term trade in Wood Group as bargain hunters step in the hope disposals go well, and cash generation improves. The longer-term picture relies heavily on the company’s ability to become free cash flow positive in the coming year and whether forecasts of an uptick in upstream investment come to pass.

This is a high-risk play for those investors who believe the oil and gas sector will contribute to the global energy supply for years to come but also see renewable infrastructure spending expanding.

Wood Group has attracted private equity interest in recent years. The recent decline may have some licking their lips.

Tip update: Transense profit growth delayed not ended

Transense Technologies (LON: TRT) shares continued to fall in price after the recent results. This is a reaction to the strategy of building up overheads ahead of growth, which has hit medium-term profit levels.
Interim figures show revenues 36% ahead at £2.46m, although pre-tax profit was 13% lower at £550,000. Hiring is going on to build up the business to cope with further growth and this is holding back profit, so that it is below previous expectations.
All parts of the business are growing their income. Royalties from iTrack rose by 26% to £1.56m. There was more modest growth for Translog...

Director deals: Chapel Down’s long-term potential

English wines maker Chapel Down Group (LON: CDGP) non-executive director Michael Spencer has bought 400,000 shares at 33.5p each. He owns 27.1% of Chapel Down.
In December, he acquired 500,000 shares at 35p each. He owns the shares through IPGL Ltd.
Business
Kent-based Chapel Down joined AIM in December 2023 at an introduction share price of 53p, having spent the previous two decades on the Aquis Stock Exchange and its forerunners. Last year, there was a strategic review of the business and there were no potential transactions that would be better than staying on AIM as an individual company.
...

AIM weekly movers: Inspiration returns

1

A contract win helped the Inspiration Healthcare (LON: IHC) share price rebound 44.4% to 19.5p. A $6m contract has been won by the Neonatal division and the core business is doing well. However, there are further delays to the Middle East contract – the first shipment is awaiting custom clearance – and revenues in the year to January 2025 were £38.3m, rather than the £40.9m forecast. Underlying revenues were 0.8% better than expected, though. The loss was more than £2m. Most of the £1.25m of annual cost savings will come through this year when there should be a return to profit. Non-executive director Richard Jones acquired 100,000 shares at 19.5p each.

Merit Group (LON: MRIT) shares recovered 28.6% to 27p ahead of the general meeting on 25 February to gain shareholder approval to leave AIM. The share price has still fallen by 15.6% this year.

Guernsey-based Sankofa Strategic Equity Fund has taken a 6.57% stake in Oxford BioDynamics (LON: OBD). The share price moved up 27.7% to 0.6p.

Media marketing platform developer SEEEN (LON: SEEN) says 2024 revenues grew from $2.1m to $3.2m following a strong second half. This suggests that the business is gaining momentum and the current annual run-rate for revenues is $5m, which is in line with forecasts. A large publisher has contracted SEEEN to manage its video library on YouTube. SEEN has IP that can maximise the income from these videos. Revenues were below forecasts but the positive outlook meant that the share price rose 23.1% to 4p.

FALLERS

TheraCryf (LON: TCF) is raising £4.25m at 0.25p/share. The share price is dived 72.5% to 0.275p. The Tuesday closing share price was 1p. The cash will finance the pre-clinical development of Orexin-1, which came with the acquisition of Chronos Therapeutics. Orexin-1 is a potential drug for a range of neuropsychiatric disorders, including addiction and anxiety. The preclinical data generated will help to attract potential partners. Former Avacta boss Dr Alastair Smith has been appointed as TheraCryf chair. He will take his fee for at least 12 months in the form of shares. 

Biome Technologies (LON: BIOM) is planning to leave AIM and is holding a general meeting on 13 March to gain shareholder agreement. Access to additional funding is difficult with a depressed share price due to trading disappointments. Management believes it will be easier to raise cash as a private company without a public share price. It will also be easier to enter into transactions without having to make announcements. There will also be cost savings. JP Jenkins will provide a matched bargains facility. The share price slumped by three-fifths to 1.5p.

Film and media localisation services provider Zoo Digital (LON: ZOO) expects full year revenues to be at least $50.5m and a return to positive EBITDA of at least $1m. These are below expectations, though. Trading recovered following the writers’ strike in Hollywood, but there have been delays and cancellations. Zoo Digital is a preferred fulfilment vendor for Amazon Prime Video and there is an increase in potential work, predominantly for existing content. Original content production remains subdued and may not recover until nearer the end of the year. This year dubbing revenues will be lower than last year. Fixed costs have been cut by one-fifth over the past year and margins are improving. The share price declined 41.1% to 16.5p, which is the lowest it has been for more than seven years.

Karelian Diamond Resources (LON: KDR) raised £323,000 at 0.75p/share. This will fund metals exploration in Northern Ireland and diamond exploration in Finland, where there are plans to advance the proposed development of the Lahtojoki deposit. The share price slipped 40.8% to 0.725p.

Aquis weekly movers: EDX Medical develops prostate cancer test

EDX Medical Group (EDX) has developed a new test for prostate cancer. The test can identify cancerous cells, whether the cancer is early stage or late stage and how aggressive the cancer is. More than 100 biomarkers are measured by the test, which is more than rival tests. Accuracy should be better than 96%. There are 55,000 cases of prostate cancer in the UK each year. Founder Professor Sir Chris Evans acquired a total of 320,000 shares at an average share price of 13.68p each, plus 20,000 shares at 13.5p each, taking his stake to 37.3%. Chief executive Dr Michael Hudson bought 45,888 shares at 10.87p each, taking his stake to 5.84%, and deputy chair Martin Walton purchased an initial 85,000 shares at 10.717p each. The share price increased 31.6% to 12.5p.

ProBiotix Health (PBX) has an agreement with Kemin China Technology, which will sell LP LDL as a cardiometabolic health ingredient in China, Hong Kong and Macau. The sales will be co-branded. Chief executive Steen Andersen has been granted 9.05 million options with an exercise price of 9.5p. They last ten years and performance criteria have to be met for them to be exercised. The share price is 31.6% higher at 12.5p.

Valereum (VLRM) has entered into an agreement with DMC Markets Inc for a cash raise of £19m. Previously it was expected to be £13m. There will be 130 million shares issue at 10p ach and 20 million shares issued at 20p each, plus a further 20 million shares at 10p each that were previously under option to Blue Sky Vision. This will be done via a new company called Valereum Inc, which will hold 48.9% of Valereum. A UK investor will invest an additional £1m at 20p/share. The cash will be invested in minority stakes in four strategic assets sourced by DMC. The share price rose 8.33% to 26p.

Mark Lyttleton has a 3.11% stake in WeCap (WCAP). The share price improved 6.98% to 1.15p.

FALLERS

Vehicle electrification technology developer Equipmake (LON: EQIP) has signed a development agreement with JC Bamford. It will develop specific power electronics for JCB. This is an initial six-month development agreement. The share price slumped 36.4% to 0.875p.

Tap Global Group (LON: TAP) has raised £1m at 2p/share and this will be invested in the fintech app platform and growing its database of registered users. The share price slipped 19.6% to 2.25p.

Coinsilium Group Ltd (LON: COIN) says portfolio company Otomato Web3 Agent Protocol, which has commenced the launch of the Otomato.xyz platform. The public launch is scheduled for the second quarter of 2025. The platform streamlines Web3 interactions. As well as its stake, Coinsilium has the rights to 7.5% of revenues generated by the platform up to the Token Listing Event. The share price fell 13.7% to 3.15p.

Marula Mining (LON: MARU) chief executive Jason Brewer is visiting the Kinusi copper mine next week. The share price dipped 10% to 4.5p.

Aquis-quoted healthcare procedures supplier One Health Group (LON: OHGR) plans to move to AIM. As part of the process, it raised £5.2m from a placing at 180p/share and existing shareholders have the chance to take up shares in an open offer of up to £500,000. A WRAP retail offer could raise up to £500,000 more. The cash will be invested in the first owned surgical hub. This will cost up to £9m and it could generate £9m of income each year. It should be earnings enhancing in the first full year of operation. The employee benefit trust (EBT), the chairman and chief medical officer are selling £2.2m worth of shares. The EBT will repay a £750,000 loan to the company. The retail offer closes on 24 February. The minimum subscription is £100. The share price declined 7.14% to 195p.

Arbuthnot Banking Group (LON: ARBB) is trading in line with expectations and is set to achieve a 2024 pre-tax profit of £34.5m. The share price edged down 3.49% to 897.5p.

Standard Chartered helps FTSE 100 carve out gains

Standard Chartered helped the FTSE 100 carve out minor gains on Friday after the Asia-focused bank wrapped up FTSE 100 banking earnings with a very respectable set of results.

The FTSE 100 was trading just 0.1% higher at the time of writing and looked like it would have to rely on the US session for a catalyst.

“Financials were in demand after a strong set of results from Standard Chartered and miners also made some progress, but there was corresponding weakness in precious metals and energy stocks,” said AJ Bell investment director Russ Mould.

“Pharmaceutical firm GSK was also on the back foot amid speculation it could be targeted by activist investors after a long period of lagging behind its rivals.”

NatWest played catch-up with the rest of the banking sector and topped the FTSE 100 with a 4% gain. Despite the numbers not being particularly bad, there was a negative reaction to NatWest’s recent results, so some may have seen the relative weakness in shares as an opportunity. 

Standard Chartered was close behind NatWest after revealing a bumper $1.5bn share buyback that far outstripped analyst estimates. Underlying Q4 operating income came in at $4.8bn, higher than the $4.5bn, and shares jumped 4% on Friday.

“Standard’s latest quarter showed continued momentum, powered by a rock-solid top line and impairments that didn’t bite as hard as expected – a pattern we’ve seen across the UK’s banking giants lately,” said Matt Britzman, senior equity analyst, Hargreaves Lansdown.

“Of course, a $342 million software impairment muddied the picture, but it won’t impact capital levels – strip it out, and pre-tax profits crushed forecasts. Standard’s Asian flair, particularly its non-interest income strength, lit up the scoreboard with wealth management shining bright. That sector’s booming in Asia, and Standard’s ready to ride the wave.”

With the FTSE 100 offering little movement, investors can find a slightly more upbeat news flow from China and developments in AI.

Since the emergence of Deepseek, closer attention has been paid to what’s happening in China in terms of AI developments and news that Alibaba plans a big push into the space was a big talking point on Friday after Chinese tech shares surged.

The strength in Chinese equities had marginal read-across into China-centric FTSE 100 stocks Prudential and Rio Tinto that ticked gently higher.

AIM movers: Europa Metals share price rebounds and Biome Technologies plans departure

3

Europa Metals (LON: EUZ) says it does not understand why the share price has fallen so sharply after trading resumed following the decision not to buy Viridian Metals Ireland, which owns the Tynagh brownfield Pb/Zn/Cu/Ag project in the Republic of Ireland. The seven million shares held in Denarius Metals Corp are worth £175,000 at 2.5p each. The company disposed of its main asset to Denarius on 13 November and it has six months from then to secure an acquisition of a business or trading in the shares will be suspended. The share price recovered 37.5% to 1.65p, but it is still 17.5% lower since returning from suspension.

Guardian Metal Resources (LON: GMET) says trenching results confirm high-grade gold mineralisation at the 100%-owned Golconda Summit project in Nevada. There is potential for an extensive Carlin-type gold system at depth. The share price rose 4.29% to 36.5p.

Kazakhstan-focused oil and gas company Caspian Sunrise (LON: CASP) has received final approval for the purchase of CS Energy and this should be completed in two months. Work can start on the West Shelva contract area and an initial exploration well could be drilled in the first half. Production could commence before the end of the year. Caspian Sunrise is raising $88m from the disposal of non-core assets and $14m has already been received. The share price improved 3.17% to 3.25p.

Proteome Sciences (LON: PRM) has won a contract to supply mass spectrometry services for analysing samples for an ongoing clinical trial. The contract with a US company is worth more than $1m and it will generate income in 2025 and 2026. The share price increased 0.45% to 4.51p, having been 4.8p earlier.

FALLERS

Bioplastics company Biome Technologies (LON: BIOM) is planning to leave AIM and is holding a general meeting on 13 March to gain shareholder agreement. Access to additional funding is difficult with a depressed share price due to trading disappointments. Management believes it will be easier to raise cash as a private company without a public share price. It will also be easier to enter into transactions without having to make announcements. There will also be cost savings. JP Jenkins will provide a matched bargains facility. The share price slumped by three-fifths to 1.5p.

Fire suppression products developer Zenova Group (LON: ZED) is raising £250,000 at 0.25p/share and each share comes with a warrant exercisable at 0.5p each. The cash will be spent on fulfilling potential orders. The share price slid 35.3% to 0.275p.  

UK Oil & Gas (LON: UKOG) has raised £400,000 via a placing at 0.0102p/share. This will be invested in the South Dorset hydrogen storage project, including its conceptual design. The share price dived 30% to 0.01225p.

Poolbeg Pharma (LON: POLB) is not going ahead with the proposed merger with HOOKPIA Pharma Inc, which decided to withdraw. The share price slipped 17.7% to 3.95p.

Tekcapital: brokers rate ‘buy’ suggesting 60% upside with more to come from Guident IPO

SP Angel has rated Tekcapital shares a ‘buy’, highlighting a potential 60% upside from the current share price.

The broker has released an update note on Tekcapital following a substantial increase in the company’s portfolio value during 2024.

Tekcapital’s portfolio grew by 38% year-on-year to reach $64.2 million on an unaudited basis, driven by robust performance across its portfolio of technology companies.

The research note emphasises a significant transformation in Tekcapital’s portfolio structure, with four of its five portfolio companies now being publicly listed, representing approximately 68% of the portfolio value. Successful IPOs of both Microsalt and GenIP were key drivers of the increase in the portfolio value, with MicroSalt trading roughly double its listing price.

SP Angel notes that this concentrated portfolio approach has enabled Tekcapital to maintain low operating expenses and run its operations efficiently.

SP Angel identifies a potentially significant catalyst in the proposed Nasdaq listing of Guident Corp, Tekcapital’s remaining unlisted investment. Guident, in which Tekcapital holds a 70% stake, operates in the rapidly expanding autonomous vehicle market that is gathering momentum amid a flurry of IPOs and wider adoption of the technology.

The analysts point to recent successful listings in this sector, citing WeRide Inc.’s share price doubling post-IPO as an indicator of strong market appetite.

SP Angel notes Guident’s strong position in the safe teleoperation of autonomous vehicles, highlighting that remote monitoring and control systems have now become mandatory in ten US states. Currently valued at $18 million in Tekcapital’s portfolio, the analysts suggest that a successful IPO could unlock significant additional value for shareholders.

On valuation, SP Angel calculates that Tekcapital’s equity and convertible loan note investments are worth approximately £45 million, translating to an asset value per share of around 24 pence. This indicates that the shares are currently trading at a substantial discount of over 55% to net asset value.

The analysts suggest a target price of 16 pence, representing a 60% upside from current levels, based on bringing the discount more in line with the investment company sector average of 35%.

Why the pound holds the key to the FTSE 100 hitting 9,000 in the near term

Despite having a fairly siggy week, the FTSE 100 is less than 5% away from touching the psychologically important level of 9,000. 

After bouncing around on either side of 8,000 for what seemed like years, the index of the UK’s top companies broke higher in the early weeks of 2025 and now has 9,000 within its sights. 

Whether the index can breach this level in the near term depends on several factors, none more important than where sterling goes in the coming weeks. 

The inverse relationship between the pound and the FTSE 100 has been the main driving force behind London’s leading index so far in 2025. A weaker pound’s favourable currency fluctuation supports companies’ earnings that are reported in dollars or euros. These companies make up a significant proportion of the FTSE 100 index and have the power to drive returns on an index level. And that they did.

The FTSE 100 hit a series of all-time highs through January and February 2025 as heavyweight overseas earners enjoyed the pounds sharp decline against the dollar.

In early 2025, poor UK economic data and concerns about the outlook were behind the pound’s weakness against the dollar, which was extenuated by relative strength in the US economy and forecasts of just one or two rate cuts by the Federal Reserve this year.

Indeed, until markets learned that UK CPI inflation rose to 3% in January, there was also a perceived divergence in the monetary policy paths of the Bank of England and the Federal Reserve. Interest rate futures markets had been pricing three or four cuts by the Bank of England compared to just one in the United States.

This set the pound on a path to the downside against the dollar and provided welcome support to the FTSE 100. This trend is now in jeopardy.

The BoE now looks unlikely to cut at its next meeting, and investors will have a close eye on any signs of inflation from wages or purchasing prices. Should inflation show signs of increasing, concerns about the BoE’s ability to reduce borrowing costs will intensify. This will be played out in the pound.

There are technical factors to consider around the FTSE 100 which underscores the importance of what the pound does next.

Such an unusually consistent rally for the FTSE 100 in early 2025 has left many companies trading at elevated levels and vulnerable to mediocre earnings. Barclays, Mondi, Marks & Spencer, and NatWest are obvious examples of investors banking profits after results didn’t knock it out of the park.

Failing a bumper surge in earnings on a constant currency basis, whether London’s leading index can test 9,000 before a meaningful correction relies heavily on the gyrations of the pound and how it can support earnings on an actual currency basis.

Share Tip: McBride – next Tuesday’s Interim Results announcement is sure to emphasise the undervaluation of this group’s shares

Despite its magnificent rise in price since featuring this private label contract packer’s shares at 24p in February 2023, up over 600%, I still believe that the group’s shares offer significant short-term upside. 
The Interim Trading Update from McBride (LON:MCB), issued on Friday 17th January this year, gave investors further confidence of better times ahead. 
The leading European manufacturer and supplier of private label and contract manufactured products for the domestic household and professional cleaning and hygiene markets, reported continued progress in revenue growth, profi...